Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.

@article{Montgomery2017CostsAE,
  title={Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.},
  author={Stephen Maxwell Montgomery and Jeanette Kusel and Richard Nicholas and Nicholas Edward Adlard},
  journal={Journal of medical economics},
  year={2017},
  volume={20 9},
  pages={962-973}
}
OBJECTIVE Patients with relapsing-remitting multiple sclerosis (RRMS) treated with disease modifying therapies (DMTs) who continue to experience disease activity may be considered for escalation therapies such as fingolimod, or may be considered for alemtuzumab. Previous economic modeling used Markov models; applying one alternative technique, discrete event simulation (DES) modeling, allows re-treatment and long-term adverse events (AEs) to be included in the analysis. METHODS A DES was… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS